A back of the envelope calculation shows that India has roughly over 680 million doses of Covid-19 vaccines consisting primarily of Covishield doses.
The third phase trial of Bharat Biotech's Covaxin began in the state on Friday and the 67-year old senior Bharatiya Janata Party leader was administered the trial dose at the Civil Hospital at Ambala Cantt.
Dominic Xavier ponders the Vaccine Dilemma: Should he take the shot or not?
The Centre on Tuesday placed orders for 44 crore doses of Covishield and Covaxin, a day after Prime Minister Narendra Modi announced that the Centre would take over the state procurement quota and provide free jabs to state governments for inoculation of all above the age of 18.
Kejriwal's announcement came after Deputy Chief Minister Manish Sisodia earlier this week claimed that Covaxin manufacturer Bharat Biotech has refused to provide additional doses to the national capital.
Amid concerns over dangerous side-effects of the Oxford's COVID-19 vaccine, India is evaluating all serious adverse events post-vaccination to determine the causality aspects of Covishield and Covaxin, an expert associated with the process said on Saturday.
"First dose (of Covishield) and then, after 12 weeks, the second dose. There is absolutely no change. Covaxin also has a two-dose schedule. First dose and then second dose after 4-6 weeks. This schedule is being followed to take our vaccination schedule forward and no confusion must be created on this," he said.
"Provide enough infrastructure and money to carry out surveillance and set up a robust routine surveillance machinery for the country to monitor any and every infectious disease'
Confirming the Drugs Controller General Of India (DCGI) approval, Serum Institute of India CEO Adar Poonawalla on Tuesday tweeted: '@SerumInstIndia's brand Covovax has completed bridging studies in India and has been granted Emergency Use Authorisation by DCGI for adults and for children above the age of 12. Younger age groups will follow shortly.'
'iNCOVACC' is priced at Rs 800 for private markets and at Rs 325 for supplies to the government of India and state governments.
The panel was informed that the economic impact of the second wave of viral infection was "asynchronous in its onset and wider in its spread particularly in rural hinterland", a source said.
As India holds its breath for the Covid vaccination to be begin, Sudhir Bisht provides a quick checklist of what you must know about the vaccines that will be administered to citizens.
"There is no sufficient supply of vaccine vials by the Centre for inoculation of above-45 age group people. Hence, the state cabinet decided to divert the stock, purchased for the 18-44 age group, for the above-45 age group," Health Minister Rajesh Tope said.
He responded to criticism in certain circles following emergency use authorisation to the vaccine and said,"Indian companies do not deserve this backlash".
The mayor conducted the inspection at The Lalit Hotel in Andheri East, during which some Brihanmumbai Municipal Corporation officials accompanied her.
Any significant adverse effect is unlikely if the second dose of a different COVID-19 vaccine is administered, but reaching a firm opinion on this will need more scrutiny and understanding, the Centre said.
A bench of Justices L Nageswara Rao and B R Gavai said bodily autonomy and integrity are protected under Article 21 of the Constitution.
Briefing the media in Rome, Goyal said the Leaders adopted the 'Rome Declaration' at the G20 Summit and the communique gives a very strong message under the health section with the countries agreeing that the COVID-19 immunisation is a global public good.
Easing restrictions, all private hospitals were on Tuesday allowed to give the vaccines if they adhere to the laid down norms, while the 9 am to 5 pm timing was also done away with.
Seventy per cent of the people who received a booster dose of the Covid vaccine did not contract the disease during the third wave, according to a new study that covered nearly 6,000 people in India.
This could also be India's first vaccine for children aged 12 years and above as the company has conducted trials on the age group. The decision, however, lies with the regulator, reports Sohini Das
Poonawalla wished the country and Prime Minister Narendra Modi success for the vaccination programme.
The Pune-based vaccine major has entered into a collaboration with the University of Oxford and AstraZeneca to manufacture the vaccine.
The Centre has accorded a security cover of armed Central Industrial Security Force (CISF) commandos for the Hyderabad premises of Bharat Biotech, one of the major COVID-19 vaccine manufacturers in the country, official sources said on Tuesday.
Such persons are expected to obtain the advice of their doctor before deciding to avail of the precaution dose or third dose.
Behind each Covid vaccine are hundreds of parents, who had the courage and conviction to come forth with their children for the trial of a vaccine which was, until then, untried in that age group, reports Sindhu Bhattacharya.
So far, 1.1 crore doses of Covaxin have been administered. Out of which 93 lakh received the first dose and out of that 4,208 (0.04 per cent) people got the infection which is four per 10,000 individuals. About 17,37,178 people received the second dose of which only 695 (0.04 per cent) tested positive for COVID-19, Bhargava said.
The company said it had conducted two separate trials for its intranasal Covid vaccine, one as a primary dose schedule and another as a booster dose, for subjects who have been double vaccinated with the two commonly administered Covid vaccines in India.
India has already asked the EU member countries to individually consider allowing Indians who have taken Covishield and Covaxin vaccines and want to travel to Europe.
"I appeal to all those who are eligible to take the vaccine. Together, let us make India COVID-19 free!" Modi said.
India is expecting 156 million doses of the vaccine from August to September, reports Ruchika Chitravanshi.
Dominic Xavier salutes every single person involved in making this miracle possible.
The Brihanmumbai Municipal Corporation (BMC) has opened vaccination booking slots for all adults from Friday evening.
The NTAGI has not yet suggested any change in the schedule of Bharat Biotech's Covaxin.
The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).
Laws governing compensation in case of adverse side effects for Covaxin and Covishield may differ in accordance with the kind of approvals given, say legal experts.
Each vaccination session will cater to a maximum of 100 beneficiaries and the Union Health Ministry has advised states not to organise 'unreasonable numbers of vaccination per site per day'.
The government on Thursday took a series of measures in view of the rising number of COVID-19 cases in several parts of the world, including China.
Replying to a question at a press conference in New Delhi, Union Health Secretary Rajesh Bhushan said, "At many places in the world, more than one vaccine are being administered, but presently, in no country, vaccine recipients have the option of choosing the shots."
Delhi on Monday sounded an alert of its depleting vaccine stock, with Health Minister Satyendar Jain saying that the national capital has only one day's Covaxin jabs left and its Covishield doses will last for just three to four days.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances